# A Study of LY3314814 in Participants With Liver Impairment

> **NCT03499041** · PHASE1 · WITHDRAWN · sponsor: **Eli Lilly and Company**

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** LY3314814

## Key facts

- **NCT ID:** NCT03499041
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-06
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Stopped for futility. Phase 3 studies not likely to meet primary endpoints.
- **Last updated:** 2018-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03499041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03499041, "A Study of LY3314814 in Participants With Liver Impairment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03499041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*